Masimo Announces CE Mark of Eve(TM) Newborn Screening

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Masimo Announces CE Mark of Eve(TM) Newborn Screening Application for Radical-7, an Intuitive Software Feature to Help Clinicians More Effectively Screen for Critical Congenital Heart Disease

NEUCHATEL, SWITZERLAND--(Marketwired - Oct 10, 2014) - Masimo ( NASDAQ : MASI ), maker of breakthrough Masimo SET ® Measure-through Motion and Low Perfusion™ Pulse Oximetry, today announced the CE Mark of Eve™ Newborn Screening Software Application* for Radical-7 ® Pulse CO-Oximeters. Eve is designed to help clinicians more effectively and efficiently screen newborns for critical congenital heart disease (CCHD).

Newborn screening protocols may sometimes present challenges, among them: longer-than-necessary monitoring times, misapplication of sensors, calculation errors, and confusion interpreting results.

The Eve Newborn Screening Software Application in the Radical-7 Pulse CO-Oximeter automates the screening steps with animated instruction, including sensor application, measurement selection, and screening result determination.

Institutions can also choose to add the Perfusion Index (PI) measurement available in all Masimo SET ® pulse oximeters to the screening criteria, which has been shown to identify CCHD or other illnesses not identified by physical exam or by SpO 2 measurements alone. 1

Use of the Eve Newborn Screening Software Application is intended to:

  • Provide consistent application of the screening protocol to reduce method and operator-induced variability
  • Improve efficiency by automating the data capture and comparison between readings.

CCHD is an umbrella term for a group of severe heart defects. All forms of CCHD affect the flow of blood into, out of, or through the heart, and if not detected and treated soon after birth can be deadly. CHD causes up to 3% of all infant deaths in the first year of life. 2 According to the U.S. Department of Health and Human Services (HHS), congenital heart defects affect up to 9 of every 1,000 live births, one quarter of which could be detected and potentially treated by measuring blood-oxygen saturation with Measure-through Motion and Low Perfusion Pulse Oximetry -- a quick, noninvasive, and inexpensive test that helps clinicians screen for potential CCHD that may signal the need for additional testing before a newborn leaves the hospital.

In 2011, an expert workgroup formed under the auspices of the HHS Secretary's Advisory Committee on Heritable Disorders in Newborns and Children recommended newborn screening with Measure-through Motion and Low Perfusion Pulse Oximetry to increase the detection of CCHD. 3 The CCHD workgroup cited the results of two large and independent prospective studies of 59,876 subjects that exclusively used Masimo SET ® Measure-through Motion and Low Perfusion Pulse Oximetry 4,5 to increase the identification of CCHD with minimal false positives.

In 2014, a third large, independent study of 122,738 newborns that also exclusively used Masimo SET ® pulse oximetry showed similar, positive results as the first two large studies. 6

Dr. Anne de-Wahl Granelli -- lead author on the groundbreaking CCHD study, liaison to the U.S. Department of Health and Human Services Secretary's Advisory Committee on Heritable Diseases in Newborns and Children (SACHDNC) workgroup, and author of an award-winning doctoral thesis in this field -- has stated: "While working at one of the two centers in Sweden that performed pediatric cardiac surgery, I found a significant difference, when compared simultaneously with blood gas, between Masimo SET and all other pulse oximetry technologies we used on cyanotic children in the PICU and pediatric cardiac ward. We were not aware of the significant difference between oximeters before this clinical study. And, as a result, we upgraded all our pulse oximeters to Masimo SET."

"Too many babies have been discharged from hospitals without proper pulse oximetry screening, only to die or require last-minute, emergency life-saving procedures," said Annamarie Saarinen, co-founder and CEO of the Newborn Foundation , and the mother of Eve, who was diagnosed at 48 hours old with CCHD. "Failing to follow and interpret a proper screening protocol, as well as being able to read measurements in newborns who are often in motion and have low perfusion are factors that can make CCHD screening with pulse oximetry a challenge. The data and study evidence show that having the right pulse oximetry technology for CCHD screening is critical -- and it's very exciting to see the introduction of Eve, a new tool that offers nurses a clearer, safer, more efficient way to conduct newborns screening and protect newborn lives."

"When we started Masimo 25 years ago, the code name for our first technology, Measure-through Motion and Low Perfusion Pulse Oximetry, was Stork. We named it Stork because we had hoped that we could with this technology help clinicians and parents deliver babies safely to their home," said Joe Kiani, founder and CEO of Masimo. "Annamarie and her daughter Eve have inspired us to name the new automated CCHD detection application, Eve. Annamarie has worked tirelessly to make CCHD screening the standard of care worldwide. We salute her and Dr. Granelli, and hope that Eve will help these professionals accomplish their mission to help save the lives of babies and spare families from heartbreaking loss."

This application is not available in the United States.

* Referred to as "CCHD Mode" in Radical-7

1 de-Wahl Granelli A et al. Acta Paediatr. 2007 Oct;96(10):1455-9. 2 Secretary of Health & Human Services letter to the Secretary's Advisory Committee on Heritable Disorders in Newborns and Children (SACHDNC); dated September 21, 2011. Available here . 3 Kemper, et al. Pediatrics. 2011 4 de-Wahl Granelli A., et al. BMJ. 2009 Jan 8;338 5 Ewer AK et al. Lancet . 2011 Aug 27;378(9793):785-94 6 Zhao Q-m, Ma X-j, Ge X-l, Liu F, Yan W-l, Wu L, Ye M, Liang X-c, Zhang J, Gao Y, Jia B, Huang G-y, Neonatal Congenital Heart Disease screening group. Pulse oximetry with clinical assessment to screen for congenital heart disease in neonates in China: a prospective study. The Lancet , Early Online Publication, 23 April 2014. doi:10.1016/S0140-6736(14)60198-7

About Masimo Masimo ( NASDAQ : MASI ) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care-helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). Additional information about Masimo and its products may be found at www.masimo.com .

Forward-Looking Statements This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our belief that Masimo SET® improves CCHD detection in newborns before hospital discharge, risks related to our assumptions of the repeatability of clinical results obtained, and risks related to our assumptions that Masimo SET® pulse oximetry technology improves patient outcomes, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov . Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks or registered trademarks of Masimo Corporation

Media Contact: Mike Drummond Masimo Corporation Phone: (949) 297-7434 Email: mdrummond@masimo.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 398

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 385

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 513

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 518

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading

Top 5 Most Recently Viewed Articles

GFI Software Celebrates Partner Excellence with 2025 Awards

Updated Category News Views 259

GFI Software Celebrates Partner Excellence with 2025 Awards GFI Software, a leader in AI-driven security and communications solutions tailored for small and medium-sized businesses, has announced its 2025 Partner Award winners. With a strong commitment to enhancing customer relationships through a dedicated partner network, GFI Software recognizes those partners who have...

Continue Reading
Join the Class Action Against Fly-E Group, Inc. Today!

Updated Category News Views 176

Important Class Action Alert for Fly-E Group, Inc. Attention investors in Fly-E Group, Inc. (NASDAQ: FLYE). There is a significant class action lawsuit that may impact your investments. If you were affected by the company's actions during the outlined period, it's crucial to know how to proceed. Understanding the context and ramifications of this lawsuit could be...

Continue Reading
Canada's Largest Clean Energy Conference Highlights Innovation

Updated Category News Views 318

Canada's Leading Clean Energy Conference Unveils Future Vision More than 2,600 attendees gathered at the largest clean energy conference and exhibition in Canada, showcasing the commitment of industry experts towards a sustainable future. This event, a hallmark of the Canadian Renewable Energy Association (CanREA), illuminated the pressing issues and opportunities within...

Continue Reading
Unlocking the Secrets of Lobster with Grant MacPherson

Updated Category News Views 182

Unleashing Culinary Creativity with Lobster Grant MacPherson, a culinary wizard with an impressive history in the kitchen, has officially launched his fourth cookbook, Viva La Lobster. This charming collection features 53 creative recipes that showcase the delightful crustacean in unconventional ways, from S'mores and Frozen Pops to the traditional Lobster Bisque. Lobster...

Continue Reading
Howmet Aerospace Stock Faces Downgrade Amid Demand Concerns

Updated Category News Views 198

Understanding KeyBanc's Downgrade of Howmet Aerospace Howmet Aerospace Inc. (NYSE:HWM) recently saw a shift in its stock evaluation when KeyBanc moved its rating from Overweight to Sector Weight. This decision comes in response to a noticeable cooling in demand within the commercial aerospace industry, prompting analysts to reconsider their outlook on the company. Despite...

Continue Reading